Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?

Tumori. 2010 Sep-Oct;96(5):794-5. doi: 10.1177/030089161009600528.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use
  • Carcinoma, Renal Cell / drug therapy*
  • Everolimus
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Molecular Targeted Therapy / methods*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Sorafenib

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Everolimus
  • Sorafenib
  • Sirolimus